The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species.
Sera from 20 species of mammals were tested for their ability to lyse erythrocytes from 18 species of mammals and birds by the alternative complement pathway. Erythrocytes were not lysed by homologous complement, with one minor exception, but all erythrocytes tested were lysed by at least one complement source, and all sera tested except that of the horse lysed at least one type of erythrocyte. Control experiments indicated that lysis was via the alternative complement pathway and that antibodies were not involved. Complement from the various species could be ranked from most active to least active, and erythrocytes could be ranked from most susceptible to least susceptible. There was an inverse correlation between complement activity and erythrocyte susceptibility. The ranking of the orders of placental mammals, from strongest to weakest complement, was carnivore > artiodactyl (ruminants and swine) > primate = armadillo > rodent > rabbit > horse. Opossum serum had activity that placed it in the centre of this range. Ferret complement, the most potent tested, lysed all erythrocytes tested except for homologous erythrocytes, with APCH50 titres as high as 4000. Although the overall reactivity pattern was clear, there were several striking exceptions. For example, the only complement source which lysed ferret erythrocytes was sera of the mouse. The amount of sialic acid present on erythrocytes of 14 mammals was determined, and was, in general, directly correlated with resistance to alternative complement pathway lysis, although there were prominent exceptions to this correlation, involving erythrocytes of the horse, burro and human. All 20 types of complement were also tested for their ability to lyse antibody-coated human tumour cells, under conditions in which both the classical and alternative complement pathways were functional. The data obtained suggest that alternative pathway activation is, in some cases, a major factor determining the effectiveness of a particular complement source in the lysis of xenogeneic tumour cells.
Ish
C
C
Center for Molecular Medicine and Immunology, Newark, New Jersey 07103.
Ong
G L
GL
Desai
N
N
Mattes
M J
MJ
D000818:Animals; D000906:Antibodies / Q000502:physiology; D003170:Complement Pathway, Alternative; D003602:Cytotoxicity, Immunologic; D004912:Erythrocytes / Q000276:immunology*; D006461:Hemolysis; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019158:N-Acetylneuraminic Acid; D051381:Rats; D017207:Rats, Sprague-Dawley; D012794:Sialic Acids / Q000502:physiology; D013045:Species Specificity; D014407:Tumor Cells, Cultured
D000906:Antibodies; D012794:Sialic Acids; D019158:N-Acetylneuraminic Acid